THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (WHICH
FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018 ("UK MAR").
NOT
FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY
PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS
UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS
ANNOUNCEMENT.
NOT
FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR
INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH
AFRICA OR JAPAN.
18 February 2025
GENINCODE
PLC
("GENinCode" or
the "Company")
(AIM: GENI.L)
Result of Retail
Offer
GENinCode plc (AIM: GENI.L), a
genetics company focused on the prevention of cardiovascular
disease ("CVD") and the
early detection of ovarian cancer,
announced on 14 February 2025 the launch of a
fundraising comprising a Placing and Subscription to raise a
minimum of £4.0 million. The Company also announced on 14 February
2025 that it intended to carry out a separate Retail Offer via
RetailBook (the "Retail
Offer" together with the Placing and Subscription,
being the "Fundraising").
The Company announced on 14 February 2025 that it had conditionally
raised £4 million through the Placing and Subscription.
The Company confirms that the Retail
Offer closed at 5.00 p.m. on 17 February 2025 and that it has
received conditional subscriptions for 1,809,508 new Ordinary Shares at the
Issue Price of 3.7 pence per share in the Retail Offer.
Following the close of the Retail
Offer, the Company has conditionally raised gross proceeds of
approximately £4.1 million at the Issue Price via the Fundraising.
The Company will therefore allot and issue an aggregate of
109,917,616 New Ordinary Shares
in connection with the Fundraising.
Each of the Retail Offer, the
Placing and the Subscription is conditional upon the fundraising
resolutions being duly passed without amendment at a General
Meeting of the Company to be held on 3 March 2025 and Admission
becoming effective at 8:00 am on or around 4 March 2025 (or such
later date as the Company and its advisors may agree, but not later
than 31 March 2025).
Capitalised terms used in this
announcement shall, unless defined in this announcement or unless
the context provides otherwise, bear the same meaning ascribed to
such terms in the launch announcement.
Admission and Total Voting Rights
Application will be made to the
London Stock Exchange for 109,917,616 New Ordinary Shares
(comprising 88,040,541 Placing Shares, 20,067,567 Subscription
Shares and 1,809,508 Retail
Shares) to be admitted to trading on AIM. Admission is expected to
take place and dealings in the New Ordinary Shares are expected to
commence at 8.00 a.m. on or around 4 March 2025, at which time it
is also expected that the New Ordinary Shares will be enabled for
settlement in CREST.
Immediately following Admission, the
issued share capital of the Company is expected to comprise
286,882,042 Ordinary Shares. Each Ordinary Share has one voting
right and no Ordinary Shares are held in treasury. Accordingly,
immediately following Admission, the total number of voting rights
in the Company will be 286,882,042. From Admission, this figure may
be used by Shareholders as the denominator for the calculation by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Notes:
References to times in this
Announcement are to London time unless otherwise stated.
The times and dates mentioned
throughout this Announcement may be adjusted by the Company in
which event the Company will make an appropriate announcement to a
Regulatory Information Service giving details of any revised dates
and the details of the new times and dates will be notified to
London Stock Exchange plc (the "London Stock Exchange") and, where
appropriate, Shareholders. Shareholders may not receive any further
written communication.
IMPORTANT INFORMATION
This Announcement is not for
publication or distribution, directly or indirectly, in or into the
United States of America. This Announcement is not an offer of
securities for sale into the United States. The securities referred
to herein have not been and will not be registered under the U.S.
Securities Act of 1933, as amended, and may not be offered or sold
in the United States, except pursuant to an applicable exemption
from registration. No public offering of securities is being made
in the United States.
This Announcement and the
information contained herein, is restricted and is not for
publication, release or distribution, directly or indirectly, in
whole or in part, in or into Australia, Canada, the Republic of
South Africa, Japan or any other jurisdiction in which such
publication, release or distribution would be unlawful.
Further, this Announcement is for information purposes only and is
not an offer of securities in any jurisdiction.
